Bernard, E.; Nannya, Y.; Hasserjian, R.P.; Devlin, S.M.; Tuechler, H.; Medina-Martinez, J.S.; Yoshizato, T.; Shiozawa, Y.; Saiki, R.; Malcovati, L.; Levine, M.F.; Arango, J.E.; Zhou, Y.; Solé, F.; Cargo, C.A.; Haase, D.; Creignou, M.; Germing, U.; Zhang, Y.; Gundem, G.; Sarian, A.; van de Loosdrecht, A.A.; Jädersten, M.; Tobiasson, M.; Kosmider, O.; Follo, M.Y.; Thol, F.; Pinheiro, R.F.; Santini, V.; Kotsianidis, I.; Boultwood, J.; Santos, F.P.S.; Schanz, J.; Kasahara, S.; Ishikawa, T.; Tsurumi, H.; Takaori-Kondo, A.; Kiguchi, T.; Polprasert, C.; Bennett, J.M.; Klimek, V.M.; Savona, M.R.; Belickova, M.; et al.

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

[rok vydání 2020, impact factor 53.440 ]

Bernard, E.; Nannya, Y.; Hasserjian, R.P.; Devlin. S.M.; Tuechler, H.; Medina-Martinez, J.S.; Yoshizato, T.; Shiozawa, Y.; Saiki, R.; Malcovati, L.; Levine, M.F.; Arango, J.E.; Zhou, Y.; Solé, F.; Cargo, C.A.; Haase, D.; Creignou, M.; Germing, U.; Zhang, Y.; Gundem, G.; Sarian, A.; van de Loosdrecht, A.; Jädersten, M.; Tobiasson, M.; Kosmider, O.; Follo, M.Y.; Thol, F.; Pinheiro, R.F.; Santini, V.; Kotsianidis, I.; Boultwood, J.; Santos, F.P.S.; Schanz, J.; Kasahara, S.; Ishikawa, T.; Tsurumi, H.; Takaori-Kondo, A.; Kiguchi, T.; Polprasert, C.; Bennett, J.M.; Klimek, V.M.; Savona, M.R.; Belickova, M.; et al.

Author correction: implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (Nature Medicine, (2020), 26, 10, (1549-1556), 10.1038/s41591-020-1008-z)

[rok vydání 2021, impact factor 53.440 ]

Bernard, E.; Nannya, Y.; Hasserjian, R.P.; Devlin, S.M.; Tuechler, H.; Medina-Martinez, J.S.; Yoshizato, T.; Shiozawa, Y.; Saiki, R.; Malcovati, L.; Levine, M.F.; Arango, J.E.; Zhou, Y.; Solé, F.; Cargo, C.A.; Haase, D.; Creignou, M.; Germing, U.; Zhang, Y.; Gundem, G.; Sarian, A.; van de Loosdrecht, A.A.; Jädersten, M.; Tobiasson, M.; Kosmider, O.; Follo, M.Y.; Thol, F.; Pinheiro, R.F.; Santini, V.; Kotsianidis, I.; Boultwood, J.; Santos, F.P.S.; Schanz, J.; Kasahara, S.; Ishikawa, T.; Tsurumi, H.; Takaori-Kondo, A.; Kiguchi, T.; Polprasert, C.; Bennett, J.M.; Klimek, V.M.; Savona, M.R.; Belickova, M.; et al.

Author correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (Nature Medicine, (2020), 26, 10, (1549-1556), 10.1038/s41591-020-1008-z)

[rok vydání 2021, impact factor 53.440 ]

Mambet, C.; Babosova, O.; Defour, J.-P.; Leroy, E.; Necula, L.; Stanca, O.; Tatic, A.; Berbec, N.; Coriu, D.; Belickova, M.; et al.

Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms

[rok vydání 2019, impact factor 16.601 ]

Prchal, J.T.; Prchal, J.F.; Belickova, M.; Chen, S.; Guan, Y.; Gartland, G.L.; Cooper, M.D.

Clonal stability of blood cell lineages indicated by X-chromosomal transcriptional polymorphism

[rok vydání 2006, impact factor 15.572]

Curik, N.; Burda, P.; Vargova, K.; Pospisil, V.; Belickova, M.; Vlckova, P.; Savvulidi, F.; Necas, E.; Hajkova, H.; Haskovec, C.; Cermak, J.; Krivjanska, M.; Trneny, M.; Laslo, P.; Jonasova, A.; Stopka, T.

5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity

[rok vydání 2012, impact factor 10.164 ]

Szikszai, K.; Krejcik, Z.; Klema, J.; Loudova, N.; Hrustincova, A.; Belickova, M.; Hruba, M.; Vesela, J.; Stranecky, V.; Kundrat, D.; Pecherkova, P.; Cermak, J.; Jonasova, A.; Dostalova Merkerova, M.

LncRNA profiling reveals that the deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 is associated with higher-risk myelodysplastic syndrome

[rok vydání 2020, impact factor 6.639 ]

Koralkova, P.; Belickova, M.; Kundrat, D.; Dostalova Merkerova, M.; Krejcik, Z.; Szikszai, K.; Kaisrlikova, M.; Vesela, J.; Vyhlidalova, P.; Stetka, J.; Hlavackova, A.; Suttnar, J.; Flodr, P.; Stritesky, J.; Jonasova, A.; Cermak, J.; Divoky, V.

Low plasma citrate levels and specific transcriptional signatures associated with quiescence of CD34+ progenitors predict Azacitidine therapy failure in MDS/AML patients

[rok vydání 2021, impact factor 6.639 ]

Hrustincova, A.; Krejcik, Z.; Kundrat, D.; Szikszai, K.; Belickova, M.; Pecherkova, P.; Klema, J.; Vesela, J.; Hruba, M.; Cermak, J.; Hrdinova, T.; Krijt, M.; Valka, J.; Jonasova, A.; Merkerova, M.D.

Circulating small noncoding RNAs have specific expression patterns in plasma and extracellular vesicles in myelodysplastic syndromes and are predictive of patient outcome

[rok vydání 2020, impact factor 6.600 ]

Votavova, H.; Urbanova, Z.; Kundrat, D.; Dostalova Merkerova, M.; Vostry, M.; Hruba, M.; Cermak, J.; Belickova, M.

Modulation of the immune response by deferasirox in myelodysplastic syndrome patients

[rok vydání 2021, impact factor 5.863 ]

Merkerova, M.D.; Remesova, H.; Krejcik, Z.; Loudova, N.; Hrustincova, A.; Szikszai, K.; Cermak, J.; Jonasova, A.; Belickova, M.

Relationship between altered miRNA expression and DNA methylation of the DLK1-DIO3 region in azacitidine-treated patients with myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes

[rok vydání 2018, impact factor 5.656 ]

Votavova, H.; Belickova, M.

Hypoplastic myelodysplastic syndrome and acquired aplastic anemia: immune‑mediated bone marrow failure syndromes (review)

[rok vydání 2022, impact factor 5.650 ]

Belickova, M.; Vesela, J.; Jonasova, A.; Pejsova, B.; Votavova, H.; Dostalova Merkerova, M.; Zemanova, Z.; Brezinova, J.; Mikulenkova, D.; Lauermannova, M.; Valka, J.; Michalova, K.; Neuwirtova, R.; Cermak, J.

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes

[rok vydání 2016, impact factor 5.168 ]

Svobodova, K.; Lhotska, H.; Hodanova, L.; Pavlistova, L.; Vesela, D.; Belickova, M.; Vesela, J.; Brezinova, J.; Sarova, I.; Izakova, S.; Lizcova, L.; Siskova, M.; Jonasova, A.; Cermak, J.; Michalova, K.; Zemanova, Z.

Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution

[rok vydání 2020, impact factor 5.006 ]

Belickova, M.; Merkerova, M.D.; Stara, E.; Vesela, J.; Sponerova, D.; Mikulenkova, D.; Brdicka, R.; Neuwirtova, R.; Jonasova, A.; Cermak, J.

DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population

[rok vydání 2013, impact factor 4.933 ]

Merkerova, M.; Vasikova, A.; Belickova, M.; Bruchova, H.

MicroRNA expression profiles in umbilical cord blood cell lineages

[rok vydání 2009, impact factor 4.791]

Dostalova Merkerova, M.; Krejcik, Z.; Votavova, H.; Belickova, M.; Vasikova, A.; Cermak, J.

Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome

[rok vydání 2010, impact factor 4.400]

Dostalova Merkerova, M.; Klema, J.; Kundrat, D.; Szikszai, K.; Krejcik, Z.; Hrustincova, A.; Trsova, I.; Le, A.V.; Cermak, J.; Jonasova, A.; Belickova, M.

Noncoding RNAs and their response predictive value in azacitidine-treated patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes

[rok vydání 2022, impact factor 4.069 ]

Votavova, H.; Grmanova, M.; Dostalova Merkerova, M.; Belickova, M.; Vasikova, A.; Neuwirtova, R.; Cermak, J.

Differential expression of microRNAs in CD34+ cells of 5q- syndrome

[rok vydání 2011, impact factor 3.990 ]

Dostalova Merkerova, M.; Bystricka, D.; Belickova, M.; Krejcik, Z.; Zemanova, Z.; Polak, J.; Hajkova, H.; Brezinova, J.; Michalova, K.; Cermak, J.

From cryptic chromosomal lesions to pathologically relevant genes: integration of SNP-array with gene expression profiling in myelodysplastic syndrome with normal karyotype

[rok vydání 2011, impact factor 3.546 ]